Statins and prostate cancer risk

A case-control study

Jackilen (Jackie) Shannon, Selome Tewoderos, Mark Garzotto, Tomasz (Tom) Beer, Rhianna Derenick, Amy Palma, Paige E. Farris

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

Observational studies have shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced cancer risk. The purpose of this case-control study was to elucidate the association between statin use and prostate cancer risk. Prostate cancer cases (n = 100), recruited upon referral for prostate biopsy, and frequency age-matched, prostate-specific antigen-normal clinic controls (n = 202) were recruited from the Portland, Oregon, Veterans Affairs Medical Center. Information on any use of statins from May 1997 through August 2004 was obtained from an electronic pharmacy database. Days of use, type of statin, dose, and prescription changes were recorded. Duration and intensity were calculated for each statin type on the basis of days of use and prescribed dose. Thirty-six percent of cases and 49 percent of controls had a record of any statin use. Following adjustment for other potential risk factors, statin use was associated with a significant reduction in prostate cancer risk (odds ratio = 0.38, 95% confidence interval: 0.21, 0.69). Furthermore, in analyses stratified by Gleason score, the inverse association with statin use was maintained only among men with Gleason scores of ≥7 (odds ratio = 0.24, 95% confidence interval: 0.11, 0.53). The results of this case-control study suggest that statins may reduce the risk of total prostate cancer and, specifically, more aggressive prostate cancer.

Original languageEnglish (US)
Pages (from-to)318-325
Number of pages8
JournalAmerican Journal of Epidemiology
Volume162
Issue number4
DOIs
StatePublished - Aug 2005

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Case-Control Studies
Prostatic Neoplasms
Neoplasm Grading
Odds Ratio
Confidence Intervals
Veterans
Prostate-Specific Antigen
Observational Studies
Prescriptions
Prostate
Oxidoreductases
Referral and Consultation
Databases
Biopsy

Keywords

  • Case-control studies
  • Cholesterol
  • Hydroxymethylglutaryl-CoA reductase inhibitors
  • Mevalonic acid
  • Prostate-specific antigen
  • Prostatic neoplasms
  • Veterans

ASJC Scopus subject areas

  • Epidemiology

Cite this

Shannon, J. J., Tewoderos, S., Garzotto, M., Beer, T. T., Derenick, R., Palma, A., & Farris, P. E. (2005). Statins and prostate cancer risk: A case-control study. American Journal of Epidemiology, 162(4), 318-325. https://doi.org/10.1093/aje/kwi203

Statins and prostate cancer risk : A case-control study. / Shannon, Jackilen (Jackie); Tewoderos, Selome; Garzotto, Mark; Beer, Tomasz (Tom); Derenick, Rhianna; Palma, Amy; Farris, Paige E.

In: American Journal of Epidemiology, Vol. 162, No. 4, 08.2005, p. 318-325.

Research output: Contribution to journalArticle

Shannon, JJ, Tewoderos, S, Garzotto, M, Beer, TT, Derenick, R, Palma, A & Farris, PE 2005, 'Statins and prostate cancer risk: A case-control study', American Journal of Epidemiology, vol. 162, no. 4, pp. 318-325. https://doi.org/10.1093/aje/kwi203
Shannon, Jackilen (Jackie) ; Tewoderos, Selome ; Garzotto, Mark ; Beer, Tomasz (Tom) ; Derenick, Rhianna ; Palma, Amy ; Farris, Paige E. / Statins and prostate cancer risk : A case-control study. In: American Journal of Epidemiology. 2005 ; Vol. 162, No. 4. pp. 318-325.
@article{f8131bb06087462db08899862ba5348b,
title = "Statins and prostate cancer risk: A case-control study",
abstract = "Observational studies have shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced cancer risk. The purpose of this case-control study was to elucidate the association between statin use and prostate cancer risk. Prostate cancer cases (n = 100), recruited upon referral for prostate biopsy, and frequency age-matched, prostate-specific antigen-normal clinic controls (n = 202) were recruited from the Portland, Oregon, Veterans Affairs Medical Center. Information on any use of statins from May 1997 through August 2004 was obtained from an electronic pharmacy database. Days of use, type of statin, dose, and prescription changes were recorded. Duration and intensity were calculated for each statin type on the basis of days of use and prescribed dose. Thirty-six percent of cases and 49 percent of controls had a record of any statin use. Following adjustment for other potential risk factors, statin use was associated with a significant reduction in prostate cancer risk (odds ratio = 0.38, 95{\%} confidence interval: 0.21, 0.69). Furthermore, in analyses stratified by Gleason score, the inverse association with statin use was maintained only among men with Gleason scores of ≥7 (odds ratio = 0.24, 95{\%} confidence interval: 0.11, 0.53). The results of this case-control study suggest that statins may reduce the risk of total prostate cancer and, specifically, more aggressive prostate cancer.",
keywords = "Case-control studies, Cholesterol, Hydroxymethylglutaryl-CoA reductase inhibitors, Mevalonic acid, Prostate-specific antigen, Prostatic neoplasms, Veterans",
author = "Shannon, {Jackilen (Jackie)} and Selome Tewoderos and Mark Garzotto and Beer, {Tomasz (Tom)} and Rhianna Derenick and Amy Palma and Farris, {Paige E.}",
year = "2005",
month = "8",
doi = "10.1093/aje/kwi203",
language = "English (US)",
volume = "162",
pages = "318--325",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Statins and prostate cancer risk

T2 - A case-control study

AU - Shannon, Jackilen (Jackie)

AU - Tewoderos, Selome

AU - Garzotto, Mark

AU - Beer, Tomasz (Tom)

AU - Derenick, Rhianna

AU - Palma, Amy

AU - Farris, Paige E.

PY - 2005/8

Y1 - 2005/8

N2 - Observational studies have shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced cancer risk. The purpose of this case-control study was to elucidate the association between statin use and prostate cancer risk. Prostate cancer cases (n = 100), recruited upon referral for prostate biopsy, and frequency age-matched, prostate-specific antigen-normal clinic controls (n = 202) were recruited from the Portland, Oregon, Veterans Affairs Medical Center. Information on any use of statins from May 1997 through August 2004 was obtained from an electronic pharmacy database. Days of use, type of statin, dose, and prescription changes were recorded. Duration and intensity were calculated for each statin type on the basis of days of use and prescribed dose. Thirty-six percent of cases and 49 percent of controls had a record of any statin use. Following adjustment for other potential risk factors, statin use was associated with a significant reduction in prostate cancer risk (odds ratio = 0.38, 95% confidence interval: 0.21, 0.69). Furthermore, in analyses stratified by Gleason score, the inverse association with statin use was maintained only among men with Gleason scores of ≥7 (odds ratio = 0.24, 95% confidence interval: 0.11, 0.53). The results of this case-control study suggest that statins may reduce the risk of total prostate cancer and, specifically, more aggressive prostate cancer.

AB - Observational studies have shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced cancer risk. The purpose of this case-control study was to elucidate the association between statin use and prostate cancer risk. Prostate cancer cases (n = 100), recruited upon referral for prostate biopsy, and frequency age-matched, prostate-specific antigen-normal clinic controls (n = 202) were recruited from the Portland, Oregon, Veterans Affairs Medical Center. Information on any use of statins from May 1997 through August 2004 was obtained from an electronic pharmacy database. Days of use, type of statin, dose, and prescription changes were recorded. Duration and intensity were calculated for each statin type on the basis of days of use and prescribed dose. Thirty-six percent of cases and 49 percent of controls had a record of any statin use. Following adjustment for other potential risk factors, statin use was associated with a significant reduction in prostate cancer risk (odds ratio = 0.38, 95% confidence interval: 0.21, 0.69). Furthermore, in analyses stratified by Gleason score, the inverse association with statin use was maintained only among men with Gleason scores of ≥7 (odds ratio = 0.24, 95% confidence interval: 0.11, 0.53). The results of this case-control study suggest that statins may reduce the risk of total prostate cancer and, specifically, more aggressive prostate cancer.

KW - Case-control studies

KW - Cholesterol

KW - Hydroxymethylglutaryl-CoA reductase inhibitors

KW - Mevalonic acid

KW - Prostate-specific antigen

KW - Prostatic neoplasms

KW - Veterans

UR - http://www.scopus.com/inward/record.url?scp=23944487796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944487796&partnerID=8YFLogxK

U2 - 10.1093/aje/kwi203

DO - 10.1093/aje/kwi203

M3 - Article

VL - 162

SP - 318

EP - 325

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 4

ER -